Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of DSM265-TPGS 34% SDD in Healthy Adults
NCT03637517Phase 1Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Oct 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DSM265 in malaria (3 arms), sponsored by Medicines for Malaria Venture. Primary endpoints: Maximum Observed Plasma Concentration at 21 days, Area Under the Plasma Concentration-Time Curve from Time Zero to 168 Hours and 4 more. Started Oct 2018; status: completed.
02
Drugs
DSM265
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03637517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03637517.